Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
The rovadicitinib deal is about more than one blood-cancer and
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
The pandemic made vaccines noisy. This acquisition is a bet
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Inside TCG Labs Soleil’s $400M Bet on Focused Biotech On
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
MOST POPULAR
